Publications by authors named "E Krasulova"
Article Synopsis
- - This study compared the effectiveness of autologous haematopoietic stem cell transplantation (AHSCT) and natalizumab in patients with progressive multiple sclerosis (MS), highlighting that AHSCT did not significantly improve disability compared to natalizumab.
- - Researchers matched 39 patients treated with AHSCT to 65 patients on natalizumab and found no significant differences in confirmed disability worsening or improvement over a period of up to 4 years.
- - Although AHSCT had some complications like febrile neutropenia and serum sickness, there were no treatment-related deaths, but the results suggest AHSCT is not effective for controlling disability in progressive MS patients with advanced disability and low relapse activity. *
Importance: Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS).
Objective: To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials.
Design, Setting, And Participants: This comparative treatment effectiveness study included 6 specialist MS centers with AHSCT programs and international MSBase registry between 2006 and 2021.
Background: COVID-19 vaccination and infection are speculated to increase the activity of immune-mediated diseases, including multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). The aim of this study was to evaluate a short-term risk of relapse after COVID-19 vaccination and COVID-19 infection in patients with these demyelinating disorders of the central nervous system and to determine disease exacerbation risk factors.
Methods: Data in this retrospective, observational cohort study was collected via the Czech nationwide registry ReMuS from March 1, 2020, to October 30, 2021.
Background: The utility of blood-brain barrier (BBB) biomarkers for clinical and magnetic resonance imaging progression in multiple sclerosis (MS) has not been extensively investigated.
Objectives: To determine whether cerebrospinal fluid (CSF) measures of BBB at clinical onset predict radiological and clinical deterioration over 48 months.
Methods: This longitudinal study included 182 patients after first clinical event suggestive of MS treated with weekly intramuscular interferon beta-1a.